Treatment of Liver Hemangioma in Kasabach-Merritt Syndrome, Giant or Growing Hepatic Haemangioma
Most hepatic haemangiomas require no intervention, but a distinct subset of patients presents with features that demand active clinical management. This protocol addresses those higher-risk scenarios.
Clinical Scenarios Covered
Kasabach-Merritt syndrome
Giant hepatic haemangioma
Growing hepatic haemangioma
Symptomatic by compression
Symptomatic or giant haemangiomas are not common, and patients falling into these categories should be referred to a benign liver tumour multidisciplinary team. In the presence of Kasabach-Merritt syndrome, growing lesions, or lesions symptomatic by compression, specialist MDT referral is recommended (evidence level III, grade of recommendation 1).
Treatment Approach
When intervention is warranted, options span both surgical and non-surgical approaches — the complete protocol defines the criteria, sequencing, and the circumstances under which each intervention applies.
References
DOI: 10.14309/ajg.0000000000002857
Symptomatic or giant haemangiomas are not common and affected individuals should be referred to a benign liver tumour MDT.
In the presence of Kasabach-Merrit syndrome, growing lesions or lesions symptomatic by compression - refer to benign liver tumour MDT (evidence level III, grade of recommendation 1)
Again, surgical resection is rarely indicated, except in the presence of KMS.
Transcatheter hepatic embolization can be considered to manage the KMS, as can medical therapy with corticosteroids or vincristine.
View source ↗